Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Payables: 2021-2024

Historic Payables for Autolus Therapeutics (AUTL) over the last 4 years, with Dec 2024 value amounting to $2.0 million.

  • Autolus Therapeutics' Payables rose 673.41% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 million, marking a year-over-year increase of 467.47%. This contributed to the annual value of $2.0 million for FY2024, which is 1811.65% up from last year.
  • Per Autolus Therapeutics' latest filing, its Payables stood at $2.0 million for FY2024, which was up 1,811.65% from $103,000 recorded in FY2023.
  • Over the past 5 years, Autolus Therapeutics' Payables peaked at $2.0 million during FY2024, and registered a low of $103,000 during FY2023.
  • Over the past 3 years, Autolus Therapeutics' median Payables value was $531,000 (recorded in 2022), while the average stood at $867,667.
  • As far as peak fluctuations go, Autolus Therapeutics' Payables slumped by 80.60% in 2023, and later skyrocketed by 1,811.65% in 2024.
  • Yearly analysis of 4 years shows Autolus Therapeutics' Payables stood at $431,000 in 2021, then rose by 23.20% to $531,000 in 2022, then crashed by 80.60% to $103,000 in 2023, then skyrocketed by 1,811.65% to $2.0 million in 2024.